|
|
|
|
|
|
|
|
CCO
Source: Biomarkers to Guide Immunotherapy Treatment of Solid Tumors: Strategies to Promote Best Practices for Quality Care
Module
Robert A. Anders, MD, PhD; Michael B. Atkins,
MD; Naiyer Rizvi, MD; and Janis M. Taube, MD, MSc, discuss the evolving
role of biomarkers to identify patients with cancer most likely to
benefit from immune checkpoint inhibitors.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the role of the immune system in pathogenesis and cancer
- Explain the mechanism of action and targeted pathways of various classes of immunotherapies
- Describe the status of emerging biomarkers being evaluated in clinical trials that may affect immunotherapy treatment decisions in the near future
- Identify patients with cancer who are likely to benefit from treatment with immunotherapy
Topics covered include:
- The Immune System in Cancer
- The Immune Response to Cancer and Opportunities for Active Immunotherapy
- Immune Checkpoint Blockade
- PD-L1 as a Potential Biomarker for Immune Checkpoint Inhibitors
- The Status of PD-L1 Biomarker Testing in the Clinic
- Other Investigational Biomarkers for Immune Checkpoint Inhibitors
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.